Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Mar 22, 2013

NEW YORK (GenomeWeb News) – Illumina said in a filing with the US Securities and Exchange Commission this week that Paul Grint plans to retire from the firm's board of directors, effective as of the next Illumina stockholder meeting.

Grint has been a director since 2005. He currently is senior VP at Forest Research Institute, and he previously was CMO at Kalypsys. He also has served as an executive at Zephyr Sciences, Pfizer, IDEC Pharmaceuticals, and Schering-Plough.

French cell chip company Cytoo has named Olivier Pasquier as its chief commercial officer. Pasquier was Qiagen's senior marketing manager in Europe before joining Cytoo. He holds an MBA from ESCP Europe and a degree in molecular biology from the French University Nice-Sophia Antipolis. In his new role at Cytoo, Pasquier will be responsible for continued sales of the company's 2D+ Cell Culture Platform as well as developing new markets in cell-based assays and screening.

Abcodia has hired Olle Nilsson to be a consultant to provide expertise on the biomarker industry and commercialization of cancer biomarkers.

Nilsson previously was VP of business development and CSO at Fujirebio Diagnostics, and he co-founded CanAg Diagnostics, which Fujirebio acquired in 2006.

Vermillion has appointed Bruce Huebner to be company chairman, taking over the post from James Burns, who will continue to serve on the board of directors.

Huebner recently was serving as Vermillion's interim CEO, until the company announced last week that it has named Thomas McLain, former CEO and CFO of Claro Scientific, to take over the CEO and president positions.

Complete Genomics said in an SEC filing this week that following the company's acquisition by BGI-Shenzhen CFO and Assistant Secretary Ajay Bansal and Senior VP, General Counsel, and Secretary A.W. Homan have both resigned as officers of the firm.

BioTheranostics said this week it has appointed Michael Dugan as its new chief medical officer and Catherine Schnabel as its VP of medical, clinical, and regulatory affairs.

Dugan formerly was VP and chief medical officer at Roche Molecular Systems. Schnabel, who joined BioTheranostics in 2009, previously handled medical affairs at Amylin Pharmaceuticals and held research roles at Genoptix and Genentech.

The Institute of Molecular Biology at Germany's University of Mainz has appointed Falk Butter to be IMB's group leader.

In the role, Butter will conduct advanced mass spectrometry projects focused on protein interactions with DNA and RNA and using quantitative proteomics to study changes that take place in the proteome over time.

Before starting at IMB, Butter worked with Matthias Mann at the Max Planck Institute for Biochemistry.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.